Get the Stockscreener App
1.15
1.77%
0.02
After Hours:
1.11
-0.04
-3.48%
Cytomed Therapeutics Ltd stock is traded at $1.15, with a volume of 13,315.
It is up +1.77% in the last 24 hours and up +20.96% over the past month.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
See More
Previous Close:
$1.13
Open:
$1.11
24h Volume:
13,315
Relative Volume:
0.83
Market Cap:
$13.61M
Revenue:
$248.40K
Net Income/Loss:
$-3.05M
P/E Ratio:
-4.4044
EPS:
-0.2611
Net Cash Flow:
$-3.30M
1W Performance:
-4.96%
1M Performance:
+20.96%
6M Performance:
-39.50%
1Y Performance:
-47.73%
1-Day Range:
$1.11
$1.206
1-Week Range:
$1.11
$1.35
52-Week Range:
$0.6801
$3.68
Cytomed Therapeutics Ltd Stock (GDTC) Company Profile
Name
Cytomed Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare GDTC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GDTC
Cytomed Therapeutics Ltd
|
1.15 | 13.37M | 248.40K | -3.05M | -3.30M | -0.2611 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cytomed Therapeutics Ltd Stock (GDTC) Latest News
CytoMed Therapeutics (NASDAQ: GDTC) director discloses holding 4,000 Ordinary Shares - Stock Titan
CytoMed Therapeutics LtdA Rising Star in Singapore's Cancer Biotechnology Sector - openPR.com
CytoMed Therapeutics(GDTC) Stock Options Chain | Quotes & News - Moomoo
CytoMed Therapeutics Limited is accelerating its international expansion - openPR.com
CytoMed Therapeutics (NASDAQ: GDTC) director reports 2,469 ordinary shares on Form 3 - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) director files initial Form 3 ownership - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) director Choo Chee Kong details direct and indirect share ownership - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) CFO reports holding 25,781 ordinary shares - Stock Titan
CytoMed Therapeutics (GDTC) chair adds 112,000 shares in private purchase - Stock Titan
[144] CytoMed Therapeutics Ltd SEC Filing - Stock Titan
GDTC Price Today: CytoMed Therapeutics Limited Stock Price, Quote & Chart | MEXC - MEXC
TradingKey - TradingKey
CytoMed Renames Subsidiary to Drive Asian and International Expansion - TipRanks
CytoMed Therapeutics (GDTC) refocuses on Asia with new subsidiary name - Stock Titan
CytoMed Therapeutics : Audited Financial Statements for FY2025 - marketscreener.com
CytoMed (GDTC) Stock Hedge Funds (Slight Downtick) 2026-04-18PCR Mean Reversion - Newser
CytoMed Therapeutics (GDTC) 2026 AGM to vote on takeover code waiver, new share issuance - Stock Titan
GDTC Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
GDTC Stock Analysis: CytoMed Therapeutics Limited gains 3 percent at 1.03 mark - Xã Châu Thành
Rising R&D loss as CytoMed (NASDAQ: GDTC) advances γδ T cell therapies - Stock Titan
CytoMed Therapeutics (NASDAQ: GDTC) flags losses and funding needs in 2025 report - Stock Titan
Stop Loss: Why is CytoMed Therapeutics Limited stock going upWeekly Trade Analysis & Community Consensus Trade Alerts - baoquankhu1.vn
AI Stocks: Can CytoMed Therapeutics Limited withstand a market correctionMarket Performance Recap & Scalable Portfolio Growth Ideas - baoquankhu1.vn
GDTC SEC FilingsCytoMed Therapeutics Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Interview with the Chairman: CytoMed Therapeutics Ltd. (NASDAQ:GDTC) - The Wall Street Transcript
GDTC Technical Analysis & ETF Price Forecast - Intellectia AI
GDTC Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
GDTC Should I Buy - Intellectia AI
GDTCCytoMed Therapeutics Ltd Latest Stock News & Market Updates - Stock Titan
CytoMed Therapeutics (NASDAQ:GDTC) Trading Up 1% – Still a Buy? - Defense World
Insider Sell: What analysts say about CytoMed Therapeutics Limited stock2025 Year in Review & Real-Time Buy Signal Notifications - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
CytoMed Therapeutics And 2 More Penny Stocks With Promising Prospects - Yahoo Finance
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Cytomed Therapeutics refutes ‘misleading’ claims, reaffirms clinical progress - Yahoo Finance
Published on: 2026-01-29 21:36:08 - baoquankhu1.vn
Cancer cell therapy company hits back at claims about its first human trial - Stock Titan
CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress - Yahoo Finance
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
CytoMed Therapeutics updates on cell therapy pipeline and trials By Investing.com - Investing.com Nigeria
CytoMed Therapeutics updates on cell therapy pipeline and trials - Investing.com
Biotech seeks investor views on share-based access to cell therapy - Stock Titan
How buybacks impact CytoMed Therapeutics Limited stock valueExit Point & Risk Controlled Daily Plans - Улправда
Is CytoMed Therapeutics Limited stock attractive after correctionJuly 2025 Technicals & Expert-Curated Trade Recommendations - DonanımHaber
How CytoMed Therapeutics Limited (F98) stock performs in volatility spikes2025 Growth vs Value & Fast Entry and Exit Trade Plans - Улправда
Is CytoMed Therapeutics Limited stock a smart buy before Fed meeting2025 Valuation Update & Daily Profit Maximizing Trade Tips - Улправда
CytoMed Therapeutics (NASDAQ:GDTC) Trading Up 7.2% – Here’s Why - Defense World
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
CytoMed stock jumps after announcing clinical trial partnership in Malaysia By Investing.com - Investing.com South Africa
CytoMed stock jumps after announcing clinical trial partnership in Malaysia - Investing.com India
Cytomed Therapeutics Ltd Stock (GDTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):